Andrew Berens
Stock Analyst at Leerink Partners
(2.42)
# 2,422
Out of 5,182 analysts
98
Total ratings
48.78%
Success rate
-1.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $27.20 | +113.24% | 11 | Mar 3, 2026 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.57 | +169.30% | 1 | Oct 31, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $36.19 | -44.74% | 6 | Jan 5, 2023 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $7.00 | +14.29% | 1 | Jan 23, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $34.92 | +14.55% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $103.86 | +43.46% | 3 | Nov 17, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $9.22 | +171.15% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $125.25 | -52.10% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $11.00 | -18.18% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $6.53 | -8.12% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $746.00 | +2.14% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $4.67 | +606.64% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $138.55 | -30.71% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $95.32 | -18.17% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $16.69 | +67.77% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $200.47 | -60.59% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $5.02 | +437.85% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $14.74 | +69.61% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $7.07 | +466.17% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.90 | +2,210.34% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $18.70 | +6.95% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $25.04 | -0.16% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $8.86 | -9.71% | 7 | Jul 14, 2017 |
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $27.20
Upside: +113.24%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.57
Upside: +169.30%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $36.19
Upside: -44.74%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $7.00
Upside: +14.29%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $34.92
Upside: +14.55%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $103.86
Upside: +43.46%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $9.22
Upside: +171.15%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $125.25
Upside: -52.10%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $11.00
Upside: -18.18%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $6.53
Upside: -8.12%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $746.00
Upside: +2.14%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $4.67
Upside: +606.64%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $138.55
Upside: -30.71%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $95.32
Upside: -18.17%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $16.69
Upside: +67.77%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $200.47
Upside: -60.59%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $5.02
Upside: +437.85%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $14.74
Upside: +69.61%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $7.07
Upside: +466.17%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.90
Upside: +2,210.34%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $18.70
Upside: +6.95%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $25.04
Upside: -0.16%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $8.86
Upside: -9.71%